Literature DB >> 11367508

Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors.

P A Kiener1, P M Davis, J L Murray, S Youssef, B M Rankin, M Kowala.   

Abstract

The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase catalyses the rate limiting step in cholesterol biosynthesis and is markedly inhibited by the statin family of drugs. The effect of statins on lipid lowering is clearly defined, but the ability of the drugs to directly regulate inflammatory functions has not been well explored. In this report, we show that there are differences among the statins in their capacity to induce proinflammatory responses both in human monocytes in vitro, and in leukocytes in mice in vivo. Treatment of human monocytes with lipophilic statins alone stimulated the production of MCP-1, IL-8, TNF-alpha and IL-1 beta and markedly sensitized the cells to subsequent challenge with inflammatory agents. Lipophilic statins also increased the production of reactive oxygen species in monocytes. In contrast, pretreatment of cells with the hydrophilic pravastatin did not induce these heightened inflammatory responses. Furthermore, treatment of mice with lipophilic statins caused a markedly higher influx of leukocytes into the inflamed peritoneal cavity following challenge with thioglycollate. Overall, these results demonstrate that the lipophilic statins influence a regulatory pathway in monocytes that controls cytokine production and that the statins induce different pro-inflammatory responses both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11367508     DOI: 10.1016/s0162-3109(00)00272-1

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  23 in total

Review 1.  Potential therapeutic role for statins in respiratory disease.

Authors:  E Hothersall; C McSharry; N C Thomson
Journal:  Thorax       Date:  2006-08       Impact factor: 9.139

2.  Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells.

Authors:  A Iwata; R Shirai; H Ishii; H Kushima; S Otani; K Hashinaga; K Umeki; K Kishi; I Tokimatsu; K Hiramatsu; J Kadota
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

3.  The effects of atorvastatin in experimental autoimmune uveitis.

Authors:  P B Thomas; T Albini; R K Giri; R F See; M Evans; N A Rao
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

4.  Association between statin use and Bell's palsy: a population-based study.

Authors:  Shih-Han Hung; Li-Hsuan Wang; Herng-Ching Lin; Shiu-Dong Chung
Journal:  Drug Saf       Date:  2014-09       Impact factor: 5.606

5.  Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol.

Authors:  Peer Wf Karmaus; Min Shi; Shira Perl; Angélique Biancotto; Julián Candia; Foo Cheung; Yuri Kotliarov; Neal Young; Michael B Fessler
Journal:  JCI Insight       Date:  2019-11-01

6.  3-Hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin)-induced 28-kDa interleukin-1β interferes with mature IL-1β signaling.

Authors:  Facundo Davaro; Sorcha D Forde; Mark Garfield; Zhaozhao Jiang; Kristen Halmen; Nelsy Depaula Tamburro; Evelyn Kurt-Jones; Katherine A Fitzgerald; Douglas T Golenbock; Donghai Wang
Journal:  J Biol Chem       Date:  2014-04-30       Impact factor: 5.157

Review 7.  Associations between statins and COPD: a systematic review.

Authors:  Claudia C Dobler; Keith K Wong; Guy B Marks
Journal:  BMC Pulm Med       Date:  2009-07-12       Impact factor: 3.317

8.  Statins for acutely hospitalized patients: randomized controlled trials are long overdue.

Authors:  Gordon R Bernard
Journal:  Crit Care       Date:  2010-04-19       Impact factor: 9.097

9.  Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.

Authors:  Anita Gianella; Elena Nobili; Mauro Abbate; Carla Zoja; Paolo Gelosa; Luciana Mussoni; Stefano Bellosta; Monica Canavesi; Daniela Rottoli; Uliano Guerrini; Maura Brioschi; Cristina Banfi; Elena Tremoli; Giuseppe Remuzzi; Luigi Sironi
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

10.  Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice.

Authors:  Birong Liao; Eileen McCall; Karen Cox; Chung-Wein Lee; Shuguang Huang; Richard E Higgs; Li-Chun Chio; Eugene Zhen; John E Hale; Nancy K Jackson; Pamela G Rutherford; Xiao-di Huang; Donetta Gifford-Moore; Kwan Hui; Kevin Duffin; Kenneth E Gould; Mark Rekhter
Journal:  Biomark Insights       Date:  2008-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.